New hope for lung failure? drug targets inflammation in ARDS
NCT ID NCT04909697
First seen May 07, 2026 · Last updated May 08, 2026 · Updated 1 time
Summary
This study tested a drug called sivelestat sodium in 324 adults with acute respiratory distress syndrome (ARDS) and systemic inflammation. The goal was to see if the drug could improve oxygen levels and reduce the need for a breathing machine. The drug works by blocking a harmful enzyme released by immune cells that damages lung tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sichuan provincial people's hospital
Chengdu, Sichuan Privince, China
Conditions
Explore the condition pages connected to this study.